Icosavax (NASDAQ:ICVX) Shares Gap Up to $25.61

Shares of Icosavax Inc (NASDAQ:ICVX) gapped up before the market opened on Tuesday . The stock had previously closed at $25.61, but opened at $27.00. Icosavax shares last traded at $22.21, with a volume of 615 shares changing hands.

Several research firms recently commented on ICVX. William Blair began coverage on shares of Icosavax in a report on Monday, August 23rd. They set an “outperform” rating and a $45.70 target price on the stock. Jefferies Financial Group assumed coverage on Icosavax in a report on Tuesday, September 14th. They set a “buy” rating and a $50.00 target price for the company. Zacks Investment Research cut Icosavax from a “hold” rating to a “sell” rating in a report on Thursday, November 18th. Evercore ISI assumed coverage on Icosavax in a report on Monday, August 23rd. They set an “outperform” rating and a C$50.00 target price for the company. Finally, Cowen started coverage on Icosavax in a report on Monday, August 23rd. They set an “outperform” rating for the company. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Icosavax has a consensus rating of “Buy” and an average target price of $48.57.

The business’s fifty day simple moving average is $28.10.

Icosavax (NASDAQ:ICVX) last announced its quarterly earnings results on Monday, November 15th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.81). As a group, sell-side analysts anticipate that Icosavax Inc will post -3.55 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada bought a new stake in Icosavax in the third quarter valued at $44,000. Citigroup Inc. bought a new stake in Icosavax in the third quarter valued at $45,000. Metropolitan Life Insurance Co NY purchased a new stake in Icosavax in the third quarter worth about $118,000. SG Americas Securities LLC bought a new stake in Icosavax during the 3rd quarter valued at approximately $179,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Icosavax during the 3rd quarter worth approximately $180,000. Institutional investors and hedge funds own 30.44% of the company’s stock.

Icosavax Company Profile (NASDAQ:ICVX)

Icosavax Inc is a biopharmaceutical company which focuses on life-threatening respiratory diseases. The company’s virus-like particle platform technology involved in developing vaccines against infectious diseases. Icosavax Inc is based in SEATTLE.

Featured Story: SEC Filing

Receive News & Ratings for Icosavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icosavax and related companies with MarketBeat.com's FREE daily email newsletter.